Department of Neurosurgery, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, PR China; Neurosurgical Clinical Research Center and Academician (Expert) Workstation of Sichuan Province, Luzhou, Sichuan, PR China; Laboratory of Neurological Diseases and Brain Functions, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, PR China.
Department of Neurosurgery, the Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, PR China.
Brain Res Bull. 2024 Oct 1;216:111050. doi: 10.1016/j.brainresbull.2024.111050. Epub 2024 Aug 13.
G protein-coupled receptor 68 (GPR68), an orphan receptor, has emerged as a promising therapeutic target for mitigating neuronal inflammation and oxidative damage. This study explores the protective mechanisms of GPR68 in cerebral ischemia-reperfusion injury (CIRI).
An in vivo middle cerebral artery occlusion/reperfusion (MCAO/R) mouse model was established. Mice received intraperitoneal injections of Ogerin, a selective GPR68 agonist. In vitro, GPR68 was overexpressed in SH-SY5Y and HMC3 cells, and the effects of oxygen-glucose deprivation/reperfusion (OGD/R) on cell viability were assessed using real-time quantitative polymerase chain reaction (RT-qPCR), enzyme-linked immunosorbent assay (ELISA), and flow cytometry.
The expression of GPR68 was suppressed in cells subjected to OGD/R treatment, whereas its upregulation conferred protection to SH-SY5Y and HMC3 cells. In vivo, levels of GPR68 were reduced in brain tissues affected by MCAO/R, correlating with oxidative stress, inflammation, and neurological damage. Treatment with a GPR68 agonist decreased brain infarction, apoptosis, and dysregulated gene expression induced by MCAO/R. Mechanistically, GPR68 agonist treatment may inhibit the activation of the NF-κB/Hif-1α pathway, thereby reducing oxidative and inflammatory responses and enhancing protection against CIRI.
This study confirms that the GPR68/NF-κB/Hif-1α axis modulates apoptosis, inflammation, and oxidative stress in CIRI, indicating that GPR68 is a potential therapeutic target for CIRI.
G 蛋白偶联受体 68(GPR68)是一种孤儿受体,已成为减轻神经元炎症和氧化损伤的有前途的治疗靶点。本研究探讨了 GPR68 在脑缺血再灌注损伤(CIRI)中的保护机制。
建立了体内大脑中动脉闭塞/再灌注(MCAO/R)小鼠模型。小鼠接受 GPR68 选择性激动剂 Ogerin 的腹腔注射。在体外,GPR68 在 SH-SY5Y 和 HMC3 细胞中过表达,并用实时定量聚合酶链反应(RT-qPCR)、酶联免疫吸附测定(ELISA)和流式细胞术评估氧葡萄糖剥夺/再灌注(OGD/R)对细胞活力的影响。
OGD/R 处理的细胞中 GPR68 的表达受到抑制,而其上调则对 SH-SY5Y 和 HMC3 细胞起到保护作用。在体内,MCAO/R 影响的脑组织中 GPR68 水平降低,与氧化应激、炎症和神经损伤相关。GPR68 激动剂治疗可减少 MCAO/R 诱导的脑梗死、细胞凋亡和基因表达失调。机制上,GPR68 激动剂治疗可能抑制 NF-κB/Hif-1α 通路的激活,从而减轻 CIRI 中的氧化和炎症反应并增强对其的保护作用。
本研究证实 GPR68/NF-κB/Hif-1α 轴调节 CIRI 中的细胞凋亡、炎症和氧化应激,表明 GPR68 是 CIRI 的潜在治疗靶点。